AI for precision medicine
Our mission is to transform drug development and improve patient outcomes with offerings that deliver novel insights for precision medicine.
Our model was developed using a curated “pathologist-in-the-loop” approach that increases model robustness. Our foundation model dramatically improves the scalability and performance of a variety of downstream tasks.
We engineer patented, “explainable” AI technologies that reduce time to model and improve performance, including an industry-leading foundation model.
We have proprietary access to high-quality, multimodal pathology data across standard of care modalities (histopathology, omics, clinical outcomes), and “future of care” modalities (e.g., mIF, proteomics, spatial transcriptomics, scRNAseq etc.) as well as bespoke data generation capabilities.
Our team has deep roots in pathology and machine learning research, and we frequently collaborate with external research partners on academic, clinical, and technical projects.
GCP-ready clinical trial platform developed under:
~
ISO 13485
certified QMS
~
ISO/IEC 27001
certified ISMS
Aignostics is a spin-off from Charité Berlin, one of Europe’s largest and most esteemed university hospitals, with an interdisciplinary team of over 100 cross-functional experts based out of Berlin and New York.
19 AI healthtechs to watch, according to VCs
World's Best Digital Health Companies 2024
10m
+
samples with access to proprietary research cohorts
55m
+
funding from blue-chip investors to date
~
2018
established in 2018, officially spun out in 2020
~
Our platform is GCP-ready clinical trial platform developed under:
~
ISO 13485
certified QMS
~
ISO/IEC 27001
certified ISMS
~
ISO 13485
certified QMS
Be part of our diverse and fast-growing team and work on problems that really matter, while being embedded in an exciting mix of tech, scientific research and medical device development.
